Cargando…

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective

BACKGROUND: Cost-effectiveness of atezolizumab, as a treatment for advanced non-small-cell lung cancer (NSCLC) patients who cannot receive a platinum-containing regimen,was still unknown. Our objective was to evaluate the cost-effectiveness of atezolizumab vs. chemotherapy in this indication from th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yunlin, Zhao, Mingye, Xi, Jiayi, Li, Jiaqi, Tang, Wenxi, Zheng, Xueping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570614/ https://www.ncbi.nlm.nih.gov/pubmed/37841712 http://dx.doi.org/10.3389/fpubh.2023.1282374

Ejemplares similares

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
por: Zhao, Mingye, et al.
Publicado: (2023)

Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China
por: Ren, Yinan, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
por: Bianco, Andrea, et al.
Publicado: (2019)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
por: Norasetthada, Lalita, et al.
Publicado: (2018)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT-INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH
por: Pianko, Matthew J., et al.
Publicado: (2023)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric Medulloblastoma in China: Based on a COG Randomized Phase II Screening Trial
por: Chen, Zhaoyan, et al.
Publicado: (2022)

Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer
por: Srinivas, K. Satish, et al.
Publicado: (2020)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis
por: Yin, Yue, et al.
Publicado: (2022)

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
por: Lyu, Wen-Wen, et al.
Publicado: (2016)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

The costs of bipolar disorder in the United Kingdom
por: Simon, Judit, et al.
Publicado: (2021)

No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom
por: White, Ellen, et al.
Publicado: (2016)

United Kingdom aid cuts: implications for financing health systems
por: McDade, Kaci Kennedy, et al.
Publicado: (2023)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Implementing Chronic Disease Self-Management Approaches in Australia and the United Kingdom
por: Browning, Colette Joy, et al.
Publicado: (2015)

Comparison of trend in chronic kidney disease burden between China, Japan, the United Kingdom, and the United States
por: Wen, Haoyu, et al.
Publicado: (2022)

Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents
por: Mountzios, Giannis, et al.
Publicado: (2013)

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
por: Borel, Christian, et al.
Publicado: (2018)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Have COVID-19-Related Economic Shocks Affected the Health Levels of Individuals in the United States and the United Kingdom?
por: Jiang, Baozhen, et al.
Publicado: (2020)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China
por: Liang, Leyi, et al.
Publicado: (2023)

PB2001: A LOOK INTO THE REAL WORLD: PICTURE OF NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE TREATED PATIENTS IN THE FRONTLINE SETTING. CARINAE STUDY
por: de Arriba de la Fuente, F., et al.
Publicado: (2022)

The hospital costs of treating lung cancer in the United Kingdom
por: Wolstenholme, J L, et al.
Publicado: (1999)

Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China
por: Ke, Xiatong, et al.
Publicado: (2021)

Health economic analysis of the integrated cognitive assessment tool to aid dementia diagnosis in the United Kingdom
por: Shore, Judith, et al.
Publicado: (2023)

Estimating recurrences prevented and costs avoided with atezolizumab in early non‐small cell lung cancer in the United States
por: Sharma, Rishika, et al.
Publicado: (2022)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3j43m0n3cna6ubsu1moba18l76